Skip to main content
. 2022 Jan 10;13(1):41. doi: 10.1038/s41419-021-04485-y

Fig. 8. Combination of aprepitant with EGFR TKIs synergistically inhibited NSCLC cell proliferation.

Fig. 8

A Cell viability of A549 and NCI-H1944 treated with gefitinib (Gefi, 10 μM) or osimertinib (Osim, 1 μM) in the presence or absence of aprepitant (Apre, 20 μM). B Cell viability of A549 and NCI-H1944 with EGFR knockdown treated with gefitinib (Gefi, 10 μM) or osimertinib (Osim, 1 μM) in the presence or absence of aprepitant (Apre, 20 μM). C, D Cell viability of A549 and NCI-H1944 treated with Apre and Osim/Gefi at indicated concentrations. FA-CI and isobologram analysis for aprepitant/osimertinib or geftinib combinations was plotted and calculated with Chou–Talalay algorithms. CI < 1 suggest synergism effect; CI = 1 suggest additive effect; CI > 1 suggest antagonism effect. Isobologram analysis represents the synergism of a combination of aprepitant with TKIs. Data were shown as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. E Working model. NK1R regulates interaction with EGFR, inducing the phosphorylation of ERK/AKT in NSCLC cells and promoting tumors progression.